Biogen Inc [BIIB] stock is trading at $159.56, up 2.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BIIB shares have gain 6.85% over the last week, with a monthly amount glided 10.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on November 06, 2025, when Stifel upgraded its rating to a Buy but kept the price target unchanged to $202 for it. Previously, Jefferies started tracking the stock with Buy rating on September 25, 2025, and set its price target to $190. HSBC Securities downgraded its rating to a Hold but stick to its price target of $118 on April 28, 2025. Argus downgraded its rating to a Hold. Bernstein started tracking with a Mkt Perform rating for this stock on February 11, 2025, and assigned it a price target of $160. In a note dated January 02, 2025, Piper Sandler downgraded a Neutral rating on this stock and revised its target price from $315 to $138.
Biogen Inc [BIIB] stock has fluctuated between $110.04 and $175.86 over the past year. Currently, Wall Street analysts expect the stock to reach $186 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $159.56 at the most recent close of the market. An investor can expect a potential return of 16.57% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Biogen Inc [NASDAQ:BIIB] reported sales of 9.69B for the trailing twelve months, which represents a growth of 3.33%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 155.86 points at the first support level, and at 152.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 161.61, and for the 2nd resistance point, it is at 163.65.
Ratios To Look Out For
For context, Biogen Inc’s Current Ratio is 2.72. Further, the Quick Ratio stands at 2.04, while the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 2.42, the price to book ratio is 1.29 and price to earnings (TTM) ratio is 14.55.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Sep 02 ’25 when 517.0 shares were sold. Officer, Singhal Priya completed a deal on Sep 02 ’25 to buy 517.0 shares. Meanwhile, Head of Global Product Strat. Izzar Rachid sold 2223.0 shares on Jul 08 ’25.
